Compare GSL & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | TNDM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | Greece | United States |
| Employees | 7 | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | GSL | TNDM |
|---|---|---|
| Price | $38.13 | $19.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $44.00 | $28.00 |
| AVG Volume (30 Days) | 358.2K | ★ 3.0M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $8.11 |
| Revenue Next Year | N/A | $11.85 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $25.15 | $10.00 |
| 52 Week High | $42.70 | $29.65 |
| Indicator | GSL | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 61.25 |
| Support Level | $35.93 | $19.70 |
| Resistance Level | $39.45 | $21.68 |
| Average True Range (ATR) | 1.23 | 1.23 |
| MACD | -0.19 | 0.72 |
| Stochastic Oscillator | 35.38 | 88.26 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.